Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update

Tuesday, May 7, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

- E2112 trial passes fourth interim analysis for OS; trial to continue, with next preplanned analysis expected in 4Q19 -

SYNDAX PHARMACEUTICALS, INC.

(unaudited)

CONDENSED CONSOLIDATED BALANCE SHEETS 

March 31,

December 31,

(In thousands)

2019

2018

Cash, cash equivalents, short-term and long-term investments

$             92,742

$             80,911

Total assets

$             99,392

$             83,938

Total liabilities

$             30,766

$             30,891

Total stockholders' equity (deficit)

$             68,626

$             53,047

Common stock outstanding 

27,095,779

24,835,951

Common stock and common stock equivalents*

41,819,938

31,088,934

*Common stock and common stock equivalents:

Common stock

27,095,779

24,835,951

Common stock warrants (pre-funded)

4,500,000

2,000,000

Common stock and pre-funded stock warrants

31,595,779

26,835,951

Options to purchase common stock

5,629,120

4,252,983

Common stock warrants (series 1 and 2)

4,595,039

-

Total common stock and common stock equivalents

41,819,938

31,088,934

SYNDAX PHARMACEUTICALS, INC.

(unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 

Three Months Ended March 31,

(In thousands, except share and per share data)

2019

2018

License fee revenue

$                  379

$                  379

Operating expenses:

Research and development

11,279

15,339

General and administrative

3,911

4,791

Total operating expenses

15,190

20,130

Loss from operations

(14,811)

(19,751)

Other income, net

509

353

Net loss 

$           (14,302)

$           (19,398)

Net loss attributable to common stockholders

$           (14,302)

$           (19,398)

Net loss per share attributable to common

stockholders--basic and diluted

$               (0.53)

$               (0.79)

Weighted-average number of common stock

used to compute net loss per share attributable 

to common stockholders--basic and diluted

27,023,466

24,478,269



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store